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A B S T R A C T
We report a first-in-patient study of vamorolone, a first-in-class dissociative steroidal anti-inflammatory drug, in Duchenne muscular dystrophy. This 2-week, open-
label Phase IIa multiple ascending dose study (0.25, 0.75, 2.0, and 6.0 mg/kg/day) enrolled 48 boys with Duchenne muscular dystrophy (4 to< 7 years), with
outcomes including clinical safety, pharmacokinetics and pharmacodynamic biomarkers. The study design included pharmacodynamic biomarkers in three contexts
of use: 1. Secondary outcomes for pharmacodynamic safety (insulin resistance, adrenal suppression, bone turnover); 2. Exploratory outcomes for drug mechanism of
action; 3. Exploratory outcomes for expanded pharmacodynamic safety. Vamorolone was safe and well-tolerated through the highest dose tested (6.0mg/kg/day)
and pharmacokinetics of vamorolone were similar to prednisolone. Using pharmacodynamic biomarkers, the study demonstrated improved safety of vamorolone
versus glucocorticoids as shown by reduction of insulin resistance, beneficial changes in bone turnover (loss of increased bone resorption and decreased bone
formation only at the highest dose level), and a reduction in adrenal suppression. Exploratory biomarkers of pharmacodynamic efficacy showed an anti-inflammatory
mechanism of action and a beneficial effect on plasma membrane stability, as demonstrated by a dose-responsive decrease in serum creatine kinase activity. With an
array of pre-selected biomarkers in multiple contexts of use, we demonstrate the development of the first dissociative steroid that preserves anti-inflammatory
efficacy and decreases steroid-associated safety concerns. Ongoing extension studies offer the potential to bridge exploratory efficacy biomarkers to clinical
outcomes.
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1. Introduction
Duchenne muscular dystrophy (DMD) is a progressive muscle dis-
ease caused by the genetic loss of dystrophin protein at the myofiber
plasma membrane. The resulting membrane instability and chronic
bouts of myofiber degeneration and regeneration trigger pathological
activation of nuclear factor of kappa B (NF-κB) inflammatory pathways.
Pathological increases in NF-κB activation is detected in dystrophin-
deficient muscle at birth, years before obvious clinical symptoms of
DMD, and this chronic inflammatory state most likely exacerbates
membrane damage and leads to disease progression [1,2]. In the ma-
jority of patients with DMD, treatment with glucocorticoid anti-in-
flammatory drugs (i.e. prednisone, deflazacort) delays disease pro-
gression and is standard of care [3,4]. However, despite their clinical
benefits, glucocorticoids have serious adverse effects that diminish
patient quality of life, including increased bone fragility and frequent
vertebral fractures, stunting of growth, delayed puberty, metabolic
disturbance and weight gain, adrenal suppression, adverse effects on
mood and behavior, and others [5]. The concerns of parents and phy-
sicians regarding adverse effects lead to variable use of glucocorticoids
in the management of patients with DMD, such that about half of pa-
tients in the United States and Europe do not receive this standard of
care [6,7].
Vamorolone (formerly VBP15) is a first-in-class steroidal drug that
shares a high degree of chemical and 3-dimensional structural
homology to glucocorticoids, and also binds the glucocorticoid receptor
(GR) and mineralocorticoid receptor (MR) with similar affinity [8–11].
Whereas glucocorticoid/GR complexes dimerize and bind to the glu-
cocorticoid response element (GRE), vamorolone/GR complexes do not
dimerize and appear to confer decreased gene transcriptional activity of
vamorolone compared to glucocorticoids [10]. This leads to retention
of drug activities associated with receptor/ligand monomers, but loss of
drug activities associated with receptor/ligand dimers. Receptor/ligand
monomers of the GR (gene NC3R1) have recently been shown to
mediate the anti-inflammatory effects of glucocorticoids by blocking
access of NF-κB transcriptional complexes to the promoter elements of
pro-inflammatory genes [12]. On the other hand, the pervasive gene
transcriptional activity of receptor/ligand dimeric complexes appear
increasingly responsible for the severe side effect profiles of gluco-
corticoid drugs, and these adverse effects are highly attenuated with
vamorolone in animal models and Phase I human clinical studies
[9,10,13–15]. The dissociation of monomeric vs. dimeric vamorolone/
GR complexes is predicted to retain efficacy and reduce safety concerns,
hence, a dissociative steroidal drug. If vamorolone is shown to be safe
and effective, it could replace glucocorticoids in the treatment of many
conditions where chronic use leads to debilitating side effects, such as
in DMD.
As the primary biochemical defect in DMD is loss of the dystrophin
protein at the myofiber cell membrane, and subsequent susceptibility to
physical membrane damage, agents able to impart greater physical
stability to the myofiber plasma membrane may ameliorate this pri-
mary cellular defect. The very high levels of serum creatine kinase (CK)
observed in patients with DMD, beginning at birth and extending
throughout life with progressive attenuation due to progressive muscle
atrophy, reflect the loss of muscle fiber membrane integrity due to
dystrophin deficiency. Glucocorticoids destabilize muscle fiber mem-
branes; serum CK levels increase rapidly with intravenous and sub-
cutaneous administration of glucocorticoids in patients with muscular
dystrophy [16,17]. In addition to inhibiting NF-ĸB, vamorolone was
developed to have a superior membrane-stabilizing activity compared
to prednisolone. In preclinical studies, vamorolone demonstrated po-
tent membrane stabilizing properties contrasting with membrane de-
stabilizing properties of prednisolone [10,16].
This Phase IIa trial of vamorolone (VBP15-002) was designed as a 2-
week open-label, sequential multiple ascending dose trial with a 2-week
washout period conducted in ambulant boys with DMD (ages 4 to<
7 years), naïve to previous treatment with glucocorticoids.
Well-established pharmacodynamic biomarkers predictive of later
clinical safety concerns of glucocorticoids were used as secondary
outcome measures. These clinically-bridged biomarkers are insulin re-
sistance (fasting glucose and insulin), adrenal suppression (first-in-
morning cortisol), and changes in bone turnover (osteocalcin and pro-
collagen type 1 pro-peptide [P1NP] [bone formation], and C-terminal
telopeptide [CTX] [bone resorption]). As these biomarkers are known
to be acutely responsive to glucocorticoids, we could accurately mea-
sure them in the 2-week treatment period and determine dose-respon-
siveness in vamorolone-treated DMD boys [18,19]. We also included
exploratory pharmacodynamic biomarkers that were previously defined
as responsive to glucocorticoids. These included 7 pro-inflammatory
serum proteins which previously showed consistent suppression after
glucocorticoid treatment in pediatric pro-inflammatory disease (DMD
and inflammatory bowel disease [IBD]), and 6 serum biomarkers sig-
nificantly increased by glucocorticoids, and were thus postulated as
markers for additional safety concerns [20,21].
2. Materials and methods
2.1. Identity of investigational medication
ReveraGen BioPharma, Inc., through a designated central pharmacy
(Almac Clinical Services, Durham. NC; Craigavon, UK), provided va-
morolone in bulk to the registered pharmacist or designated staff at
each study site. Vamorolone active pharmaceutical ingredient was
manufactured by Olon Ricerca Biosciences (Concord, OH). Vamrolone
drug product was manufactured by Velesco Pharmaceutical Service
(Kalamazoo, MI) and supplied as a cherry-flavored suspension (4% by
weight). Bulk vamorolone supply was stored at refrigerated tempera-
ture (2–8°C; 3646 °F). Excursions to ambient temperature were allowed.
2.2. Laboratories
This study utilized a central clinical laboratory (ACM Medical
Laboratory, Inc., Rochester, NY; York, UK; Singapore). In addition to
clinical safety parameters, this central laboratory also performed ana-
lysis on the following biomarkers: osteocalcin, P1NP, CTX, fasting
glucose, fasting insulin. Analysis of morning cortisol was performed by
PRA Health Sciences (Groningen, the Netherlands) via immunoassay.
Analysis of glutamate dehydrogenase (GLDH) was performed by
Randox Laboratories Ltd. (Antrim Co. Antrim, UK) via immunoassay.
Exploratory biomarker analyses were performed by SomaLogic Inc.
(Boulder, CO) via their proprietary SOMAscan™ aptamer profiling assay.
2.3. Study design and conduct
The trial design was a multi-center, open-label, sequential multiple
ascending dose study evaluating the safety, PK, PD, and exploratory
efficacy following oral administration of vamorolone 0.25, 0.75, 2.0,
and 6.0mg/kg/day for two weeks, with two-week follow-up off drug, in
boys ages 4–<7 years of age with DMD. The study was approved by
the Institutional Review Board at each participating site. The legal
guardian for each study participant signed informed consent prior to
any study procedures. The primary objective of this study was to
evaluate the safety of multiple ascending oral doses of vamorolone in
ambulant boys ages 4-< 7 years of age with DMD. The secondary ob-
jectives were to investigate the single-dose and multiple-dose PK of oral
vamorolone at multiple dose levels, and to investigate the effects of
single and multiple oral doses of vamorolone on serum PD biomarkers.
Secondary objectives included evaluation of biomarkers bridged to
clinical outcomes. The exploratory objectives were to evaluate bio-
markers of safety and efficacy that were not yet bridged to clinical
outcomes. Main criteria for inclusion were male subjects, 4–<7 years
of age at study entry, diagnosed with DMD by confirmed dystrophin
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deficiency, who were able to complete the Time to Stand Test without
assistance at the study Screening and Baseline Visits. The study was
conducted by the Cooperative International Neuromuscular Research
Group (CINRG) at 11 United States (US) and non-US study sites. Twelve
subjects were assigned to each of the 4 dose cohorts and received an
oral dose of vamorolone once daily with 8 ounces of whole milk (or
equivalent high fat food portion). Following completion of this study,
participants had the option to enroll in a 6-month open label extension
study (VBP15-003), and then a 24-month, open-label long-term exten-
sion study (VBP15-LTE).
2.4. Sample size
A sample size of 12 subjects in each cohort was determined to be
sufficient, with the following considerations: a sample size of 12 sub-
jects is large enough to have a confidence interval of no wider than 50%
for the proportion of adverse events assessed or any other event out-
come. For continuous outcomes such as safety laboratory markers or PD
biomarkers, a two-sided 95.0% confidence interval for the mean will be
no wider than 0.8 standard deviations (SD) from the observed mean,
with 90.0% coverage probability, based on the t statistic; thus, the total
confidence interval will be approximately 1.6 SDs wide for any con-
tinuous parameter if its underlying distribution is approximately
normal.
2.5. Analysis populations
Two analysis populations were defined for this study. The Safety
Population consisted of all subjects who received at least one dose of
study medication. The Safety Population was used for safety and PD
analyses. The PK Population consisted of all subjects who received at
least one dose of study medication and had sufficient quantifiable
plasma concentration data for PK analysis.
2.6. Safety
Safety was assessed by clinical laboratory analyses, treatment, and
post-treatment; physical examinations with weight, vital sign mea-
surements, and 12-lead ECG were performed during the pre-treatment,
treatment, and post-treatment periods. Adverse events (AEs) were
monitored throughout the course of the study. The liver-selective en-
zymes glutamate dehydrogenase (GLDH) and gamma-glutamyl trans-
ferase (GGT) were studied as exploratory biomarkers in VBP15-002 to
monitor potential vamorolone induced liver injury [22–24].
2.7. Pharmacokinetic methods
Analysis of plasma concentrations of vamorolone was performed
using a validated LC–MS/MS method (PRA Health Sciences, Lenexa,
KS). All PK parameters were calculated using noncompartmental ana-
lysis (NCA). For the pharmacokinetic analysis, negative plasma con-
centrations that occurred at pre-dose time (0 h) were treated as zero (0).
All other concentrations were included in the PK analysis. Nominal/
Relative times were identical for all data used in this study. The NCA
was performed using Phoenix® WinNonlin® (Certara). All concentration-
time graphs were prepared using Matlab® R2016b for Windows®. The
maximum plasma concentration (Cmax) and time to Cmax (tmax) were
taken directly from the data. For the calculation of the AUClast and
AUCinf, the option linear up-log down trapezoidal method was chosen
with uniform weighting of the data. The elimination rate constant, kel,
was calculated as the negative of the slope of the terminal log-linear
segment of the plasma concentration-time curve. For the cases where
the subjects showed a clear washout phase (by visual inspection), at
least 3 terminal plasma concentration time points were selected for
determination of kel. For subjects not showing such clear elimination, kel
was assumed to be equal to the average kel of the rest of the subjects
who received the same dose. The AUCinf was calculated as: AUCinf =
AUClast + Clast/kel.where Clast is the final concentration. Elimination
half-life (t½) was calculated according to: t1/2 = ln (2)/kel. Clearance
(CL), uncorrected for bioavailability, was calculated as CL=Dose/
AUCinf.
2.8. Pharmacokinetic analysis
The primary objectives of the PK analysis were: 1) to investigate the
first- and multiple-dose PK of oral vamorolone, and 2) to explore line-
arity of the different doses administered in boys ages 4 to< 7 years
with DMD. The secondary objective of the PK analysis was to compare
the PK of vamorolone in boys with DMD and healthy adult male sub-
jects who participated in the Phase I Randomized, Placebo-Controlled,
Double-Blind, Single Ascending Dose and Multiple Ascending Dose
Study [9]. All subjects who received at least one dose of vamorolone
study medication and had sufficient data for PK analysis were included
in the PK Analysis Population. Twelve subjects were assigned to each of
the 4 cohorts and received an oral dose of vamorolone once daily with 8
ounces of whole milk (or equivalent high fat food portion). In the Phase
I VBP15-001 study in healthy adult volunteers, vamorolone showed
enhanced bioavailability with a fat meal, as has also been observed with
other hydrophobic steroidal drugs [9]. Blood sample times for the de-
termination of vamorolone plasma concentrations were as follows: Day
1:0 (pre-dose), 1, 2, 4, 6, 8 h; Day 14:0 (pre-dose), 1, 2, 4, 6, 8 h. Forty-
seven subjects had evaluable PK data and were included in the PK
Analysis Population.
2.9. Pharmacodynamics
To address the safety concerns associated with glucocorticoids,
pharmacodynamic (PD) biomarkers that are bridged to later clinical
safety concerns of glucocorticoids were studied as secondary outcomes.
These comprised PD biomarkers of insulin resistance (fasting glucose,
fasting insulin), low bone mineral density (PD biomarkers of bone
turnover [serum osteocalcin, P1NP, and CTX]), and adrenal axis sup-
pression (first-in-morning cortisol). Serum osteocalcin, P1NP, and NTX
(N-terminal telopeptide, a comparable bone resorption biomarker)
were previously shown to respond to glucocorticoid treatment within
the 2-week treatment time frame that was incorporated in the VBP15-
002 study [18,19].
Fasting serum glucose and insulin were measured at Baseline (0.5 h
pre-dose Day 1) and Week 2 (0.5 h pre-dose Day 14). Insulin was
measured quantitatively using the ADVIA Centaur® Insulin assay, a two-
site sandwich immunoassay using direct chemiluminescent technology
(Siemens Healthcare Diagnostics, Tarrytown, NY USA). Osteocalcin,
P1NP, and CTX, were measured at the screening visit (blood drawn in
the afternoon) and Week 2 (blood drawn 6 h post morning dose); these
times were chosen to minimize confounding diurnal variations.
Osteocalcin was quantified using LIASON® Osteocalcin, a chemilumi-
nescence immunoassay (DiaSorin, Stillwater, MN). CTX was quantified
by the β-CrossLaps electrochemiluminescence immunoassay (Roche
Diagnostics, Indianapolis, IN). P1NP was quantified using the Total
P1NP electrochemiluminescence assay (Roche Diagnostics,
Indianapolis, IN). All tests were designed for quantitative determination
in human serum.
Glucocorticoids impact the hypothalamic-pituitary-adrenal (HPA)
axis through negative feedback loops, and pharmacological gluco-
corticoids cause transient but significant reductions in the secretion of
cortisol by the adrenal cortex within hours of a single, oral dose [18].
The measurement and interpretation of adrenal hormones is also af-
fected by circadian variation with a peak serum cortisol level pre-
awakening followed by a rapid fall in serum cortisol post-awakening,
hence the importance of timing of blood collection relative to time of
day. Prolonged dosing of patients with pharmacological glucocorticoids
leads to adrenal suppression - which is caused by chronic suppression of
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the HPA axis- and, in turn, a chronic decrease in endogenous cortisol
production [25,26]. First-in-morning cortisol can be used as a screening
tool for chronic adrenal suppression, and in patients with normal cir-
cadian regulation, first-in-morning serum cortisol levels< 3.6 μg/dL
(100 nmol/L) suggest chronic adrenal suppression [27,28]. First-in-
morning blood cortisol levels were obtained ∼24 h after the previous
dose of vamorolone at the 2-week visit. Cortisol was measured using the
ADVIA Centaur® cortisol immunoassay, designed for quantitative de-
termination in serum (Siemens Healthcare Diagnostics, Tarrytown, NY
USA).
Serum creatine kinase (CK), an abundant enzyme in muscle fibers,
was pre-specified as an exploratory pharmacodynamic efficacy bio-
marker in the Phase IIa protocol. Serum CK is elevated in the setting of
muscle membrane damage caused by muscular dystrophy. To test if
vamorolone improves membrane stabilization, serum CK activity was
measured at Baseline, after two weeks of treatment with vamorolone,
and after two weeks of washout following the last dose of vamorolone.
The CK activity was measured by ADVIA® Chemistry Systems (Siemens
Healthcare Diagnostics, Tarrytown, NY USA), an assay developed for
human serum/plasma.
2.10. SOMAscan assays
Serum from a subset of 39 subjects was accessioned for SOMAscan™
aptamer profiling. The number of subjects evaluated at each dose level
was 7 at 6.0 mg/kg, 10 at 2.0 mg/kg, 11 at 0.75mg/kg and 11 at
0.25mg/kg. Number of subject per dose level varied because
Somalogic™ ended performance of contractual assays, and therefore
only samples accessed by December 1, 2017 were available for testing.
Two serum samples were tested for each subject; Baseline (pre-treat-
ment), and after two weeks of daily treatment with vamorolone at the
indicated dose level. The Baseline sample was obtained during a
Screening Visit prior to Study Day -1, in the afternoon. The sample
following two weeks of treatment was obtained 6 h after the morning
dose. The SOMAscan™ assay measures 1310 serum proteins, over a 10
[8] dynamic range, using modified nucleic acid probes that are specific
Table 1
Demographics and Clinical Information from 48 Study Participants. Abbreviations: W=white; B=black; A=Asian; Unk= unknown; Non H/L= not Hispanic or
Latino; H/L=Hispanic or Latino; del= deletion; dupl= duplication; n/a = not available; TTSTAND=time to stand test from the floor; m/s=meters per second.
Dose
Level
(mg/kg)
Age at Enrollment (years) Race Ethnicity Mutation type Starting exon Baseline TTSTAND Velocity
(m/s)
Baseline TTSTAND Seconds
0.25 6 W Non H/L Multiple Exon Del 8 0.13 7.85
4 W Non H/L Multiple Exon Del 8 0.18 5.53
4 W Non H/L Multiple Exon Del 47 0.26 3.9
6 B Non H/L Multiple Exon Del 51 0.13 7.59
6 W Non H/L No large del/ dupl n/a 0.14 7.3
6 W Non H/L Single Exon Del 45 0.2 5
6 W Non H/L No large del/ dupl n/a 0.1 10.2
6 W Non H/L No large del/ dupl n/a 0.27 3.65
4 W Non H/L Multiple Exon Del 8 0.16 6.44
4 W Non H/L Multiple Exon Del 45 0.13 7.8
4 W Non H/L Multiple Exon Del 10 0.29 3.4
6 W Non H/L Multiple Exon Del 52 0.22 4.5
0.75 6 A Non H/L Multiple Exon Del 8 0.14 7.14
4 W Non H/L Single Exon Del 44 0.25 4.02
4 W Non H/L Multiple Exon Del 46 0.12 8.4
5 Unk Hisp or Lat Single Exon Del 45 0.13 7.8
5 W Non H/L Multiple Exon Del 45 0.13 7.97
4 W Non H/L Multiple Exon Del 5 0.33 3.06
4 W Non H/L Multiple Exon Del 51 0.33 3
4 W Non H/L Multiple Exon Del 16 0.23 4.31
6 W Non H/L Multiple Exon Del 48 0.27 3.7
5 W Non H/L Multiple Exon Del 49 0.31 3.2
6 W Non H/L Multiple Exon Del 49 0.38 2.8
5 W Non H/L Single Exon Del 51 0.27 3.7
2.0 4 W Non H/L Multiple Exon Del 22 0.28 3.6
4 W Non H/L No large del/ dupl n/a 0.18 5.7
4 W Non H/L Multiple Exon Del 33 0.17 6.03
4 W Non H/L Single Exon Del 50 0.12 8.5
4 W Non H/L Multiple Exon Del 53 0.16 6.1
6 W Non H/L Multiple Exon Del 3 0.26 3.8
4 W Non H/L Multiple Exon Del 45 0.11 9.2
5 W Non H/L Multiple Exon Del 48 0.26 3.9
6 W Non H/L Multiple Exon Del 3 0.21 4.7
5 W Non H/L No large del/ dupl n/a 0.29 3.5
6 W Non H/L Multiple Exon Del 8 0.26 3.9
4 W Non H/L Single Exon Del 8 0.4 2.5
6.0 5 W Hisp or Lat Multiple Exon Del 48 0.15 6.5
5 W Hisp or Lat Single Exon Del 45 0.16 6.4
5 W Non H/L Multiple Exon Del 44 0.14 7
5 W Non H/L Multiple Exon Del 48 0.25 4
6 W Non H/L Single Exon Del 51 0.24 4.1
4 W Non H/L Single Exon Del 52 0.07 14.06
4 W Non H/L Single Exon Dupl 12 0.26 3.81
4 W Non H/L Single Exon Del 7 0.21 4.7
4 W Non H/L Multiple Exon Del 48 0.16 6.15
4 W Non H/L Single Exon Del 44 0.23 4.31
6 W Non H/L No large del/ dupl n/a 0.2 5
5 W Non H/L Single Exon Del 45 0.21 4.8
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and sensitive for each of the proteins (aptamers). The aptamers gen-
erally bind to a larger epitope than do antibodies, and thus can be both
more specific and also identify three dimensional structures (e.g. mul-
timeric protein complexes). Because the detection reagents are nucleic
acids, the method enables amplification of signals using PCR, and ad-
dressing of detection aptamer reagents using sequence tags. Serial di-
lutions of 70 μL of sera are used to assay each protein in the center of its
standard curve. Data for each subject studied was received for all 1310
proteins from SomaLogic™ with global normalization of all relative
protein unit values. A data filter was then applied so that only data from
the pre-specified 7 efficacy and 6 safety biomarkers were analyzed
(Figs. 2 and 3).
2.11. Statistical analysis
All statistical tests were two-sided and a resultant p-value of less
than or equal to 0.05 was considered significant. Descriptive summaries
of variables were provided where appropriate. In general, for con-
tinuous variables, the number of non-missing values (n) and the mean,
standard deviation (SD), median, minimum, and maximum were ta-
bulated. Unless otherwise noted, baseline was defined as the last
measurement taken prior to first exposure to study drug, including Day
1 pre-dose measurements. Analyses were performed using Statistical
Analysis System (SAS) (release 9.4) for Windows™. No adjustments for
multiplicity on inferential statistical testing were performed in this
study. Outliers were not removed. Analyses of the SOMAscan™ bio-
markers were performed using GraphPad Prism™. Assay results are
reported in Relative Fluorescence Units (RFUs). Mean percentage
change from baseline in serum RFUs are summarized by dose level. For
each biomarker, data were log transformed, and a parametric 2-tailed,
paired-sample t-test was conducted to compare pre-treatment to post-
treatment. A time-line graph was created presenting mean and subject-
level change from baseline response, by biomarker and dose level.
3. Results
VBP15-002 was a 4-week, Phase IIa multiple ascending dose trial,
comprised of two weeks of daily treatment with vamorolone followed
by a two-week washout period in steroid-naïve, 4 to< 7 year old boys
with DMD. Twelve patients were recruited in each of four dose groups
(0.25, 0.75, 2.0, and 6.0mg/kg/day) (48 patients total). Clinical safety
through adverse event reporting was collected throughout the study.
The demographic and clinical information for the subjects enrolled are
reported in Table 1.
All study participants completed the 4-week VBP15-002 Phase IIa
study and were invited to enroll in a 24-week Phase II extension study
(VBP15-003) at the same dose level, and in the long term extension
study that followed (VBP15-LTE).
3.1. Clinical safety assessment
There were no clinically significant safety concerns during the
study, as assessed by clinical laboratory analyses, physical examina-
tions with body mass index (BMI), vital sign measurements, and 12-lead
electrocardiogram (ECG) performed during the pre-treatment
(Baseline), treatment (2 weeks), and post-treatment washout periods (2
weeks). During the trial, there were a total of 46 treatment-emergent
adverse events (TEAEs) among the 48 subjects. The TEAEs with the
highest incidence were viral upper respiratory tract infection (12.5%),
diarrhea (8.3%), pain in extremity (6.3%) and vomiting (6.3%). Twenty
subjects (41.7%) had TEAEs that were considered by the investigator to
be remotely related or unrelated to study drug, and 8 subjects (16.7%)
had TEAEs that were considered by the investigator to be possibly or
probably related to study drug. No subject had a TEAE that was as-
sessed as definitely related to study drug. Twenty-six subjects (54.2%)
had TEAEs considered by the investigator to be mild in severity, and
two subjects (4.2%) had TEAEs considered by the investigator to be
moderate in severity. No subject had a TEAE considered to be severe, or
a TEAE that resulted in discontinuation from the study. There were no
serious adverse events (SAEs). There were no clinically significant
changes from baseline with respect to BMI, ECG findings, clinical la-
boratory values, or vital signs.
Drug-induced liver injury is typically monitored by alanine amino-
transferase (ALT) and aspartate aminotransferase (AST). However, as
expected, all DMD participants showed muscle disease-related elevation
of serum ALT and AST at baseline, prior to any drug treatment. The
liver-selective enzymes GLDH and GGT were studied as exploratory
clinical laboratory tests in VBP15-002 to monitor potential vamor-
oloneinduced liver injury [20–22]. No dose-related persistent eleva-
tions of GLDH or GGT were seen, suggesting that vamorolone does not
confer acute or subacute hepatic toxicity.
3.2. Pharmacokinetic assessment
In boys with DMD, oral vamorolone was absorbed at a moderate
rate with peak concentrations typically occurring at 2 or 4 h on both
Days 1 and 14. The drug half-life across all doses was similar on both
days, averaging about 2 h. Peak concentrations and AUCinf values were
generally comparable on Days 1 and 14 for each of the dose levels. The
mean ratios on Day 14 to Day 1 were 1.7 with a SD of 1.0 for Cmax and
2.5 with a SD of 5.1 for AUCinf. The large mean and SD of the AUCinf
ratio is mainly driven by a single participant (Cohort 4–6mg/kg) who
on Day 1 had a very low AUCinf, probably due to low bioavailability of
vamorolone. The mean AUCinf ratio for Day 14/Day 1 excluding this
participant is 1.7 with SD 1.3. A summary of the observed (Cmax and
tmax) and calculated (AUCinf, t1/2, and CL) pharmacokinetic parameters
for all doses for Day 1 and Day 14 is provided in Table 2.
Clearance was consistent across the Day 1 dose levels as well as for
the Day 14 dose levels, but the latter tended to average slightly lower
(about 2400mL/h/kg on Day 1 and 1900mL/h/kg on Day 14). Overall,
higher doses resulted in higher plasma concentrations of vamorolone,
as expected. In particular, plasma drug concentrations versus time
showed a rapid to moderate rate of absorption, a maximum (Cmax) at a
tmax of 2 or 4 h, and a decline phase with a typical t1/2 of 2 h. For all
Table 2
Summary of pharmacokinetic parameters for vamorolone after oral administration of 0.25, 0.75, 2.0 and 6.0 mg/kg doses once daily. Values are mean (SD) and
fortmax mean [median] (SD). Abbreviations: Cmax=maximum peak concentration; tmax= time at which Cmax is observed; AUC=area under the curve; t1/2=half-
life; CL=clearance.
Dose, mg/kg/day Day 1 Day 14
0.25 0.75 2.0 6.0 0.25 0.75 2.0 6.0
Cmax [ng/ml] 22.9 (13.4) 75.9 (25.9) 199 (111) 855.6 (471) 32.2 (15.2) 124.7 (42.5) 252.5 (96) 970 (270)
tmax [hr] 3.6 [4] (1.2) 4.6 [4] (2.1) 2.5 [2] (1.3) 2.7 [2] (1.3) 3.8 [4] (1.8) 3.8 [4] (2.2) 2.8 [2] (1) 2.3 [2] (0.86)
AUCinf [hr∙ng/ml] 118 (48) 379 (117) 761 (352) 3279 (1693) 164 (61) 544 (155) 1138 (467) 3606 (897)
t1/2 [hr] 2.1 (0.85) 1.8 (0.43) 1.9 (0.79) 1.9 (0.95) 1.9 (0.96) 2.1 (0.8) 1.9 (1.02) 1.4 (0.35)
CL [ml/hr/kg] 2459 (897) 2285 (1103 2697 (1285 2320 (1375) 1828 (919) 1509 (482) 2047 (771) 1777 (476)
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doses investigated, the mean PK profiles on Day 1 and Day 14 appear
similar; no drug accumulation between doses was observed, consistent
with the short half-life and daily dose schedule. In conclusion, the PK of
vamorolone was similar to that of glucocorticoids such as prednisolone.
3.3. Serum pharmacodynamic safety biomarker measures bridged to clinical
outcomes
3.3.1. Insulin resistance measured by fasting insulin and glucose
Mean fasting glucose and mean fasting insulin levels were compared
between Baseline (0.5 h pre-dose Day 1) and Week 2 (0.5 h pre-dose
Day 14). At both Baseline and Week 2, mean levels of fasting glucose
were within the normal range (60–99mg/dL) for this age group for all
vamorolone dose level groups. The mean changes from Baseline to
Week 2 in fasting glucose were clinically unremarkable and not sig-
nificant for any dose level group. There were no appreciable changes in
mean fasting insulin levels at the 0.25, 0.75, or 2.0 mg/kg dose levels.
At the 6.0mg/kg dose, the mean (± SD) fasting insulin increased from
3.96 ± 2 μIU/mL to 6.73 ± 4.6 μIU/mL (paired t-test, p-value 0.063).
All data for fasting glucose and insulin by dose level group are shown in
Supplemental Table S1.
3.3.2. Bone turnover markers
After 2 weeks of daily treatment with vamorolone at 2.0 and
6.0 mg/kg doses, there was a significant decrease in CTX (bone re-
sorption) correlated with increasing dose level (intragroup paired t test:
2.0 mg/kg, p= 0.006; 6.0mg/kg, p= <0.001 (Table 3). Osteocalcin
(bone formation) decreased significantly only at the 6.0 mg/kg dose
level (intragroup paired t test; p= <0.001). At vamorolone doses of
2.0 and 6.0mg/kg, significant decreases in P1NP (bone formation)
were also observed (intragroup paired t test: 2.0 mg/kg, p= <0.001;
6.0 mg/kg, p= <0.001 (Table 2). However, there was also a sig-
nificant decrease observed at 0.25mg/kg, demonstrating a pattern of
unclear dose-responsiveness of P1NP (paired t test; p= 0.01).
3.3.3. Adrenal suppression measured by first-in-morning cortisol
Mean values of the 2week first -in-morning cortisol 24 h after the
last drug dose were 10.43 for 0.25mg/kg, 9.76 for 0.75mg/kg, 7.32 for
2.0 mg/kg, and 3.01 μg/dL for 6.0 mg/kg. After 2 weeks of daily
treatment, a depressed morning cortisol (< 3.6 μg/dL [100 nmol/L])
consistent with adrenal suppression was observed in 0 of 11 tested
participants who received 0.25mg/kg, 0 of 11 tested participants who
received 0.75mg/kg, 2 of 11 (18.2%) tested participants who received
2mg/kg, and 6 of 10 (60.0%) tested participants who received va-
morolone 6mg/kg (Fig. 1).
Findings in boys with DMD were similar to those previously re-
ported in healthy adult volunteers receiving a daily dose of vamorolone
for 2 weeks, where 0% of adults treated with 1mg/kg, 0% of adults
treated with 3mg/kg, 50% of adults treated with 9mg/kg, and 100% of
adults treated with 20mg/kg showed adrenal suppression [9].
3.4. Exploratory pharmacodynamic biomarkers
Six exploratory safety biomarkers defined in glucocorticoid-treated
DMD and IBD children [20] were tested in the VBP15-002 trial. Two
(angiotensinogen [AGT] and afamin [AFM]) showed treatment-asso-
ciated increases, with higher doses of vamorolone leading to greater
mean increases in protein levels, in a pattern similar to glucocorticoids.
The additional four proteins did not increase in a pattern that correlated
with dose level (MMP-3, insulin, leptin, IGFBP-5) (Fig. 2). A summary
of means data by biomarker and dose level can be found in Supple-
mental Table S2. A summary of paired analysis data (parametric, two-
tailed paired t-test) can be found in Supplemental Table S3.
Seven pre-specified exploratory efficacy biomarkers (pro-in-
flammatory proteins) responsive to glucocorticoid treatment in DMD
and IBD were tested [20]. Six (CD23, MDC, IL-22BP, IGFBP-2, LTa1/b2,
and MMP-12) showed doseresponsive decreases with increasing doses
of vamorolone, with the greatest decreases from baseline occurring at
the highest doses (Fig. 3). Only ITGA1/ITGA2 (integrin complex)
showed no pattern of dose response, and this biomarker also showed
lack of validation in IBD in the original discovery/validation report
[20]. These data provide strong support for the anti-inflammatory
mechanism of action of vamorolone.
A summary of means data by biomarker and dose level can be found
in Supplemental Table S4. A summary of paired analysis data (para-
metric, two-tailed paired t-test) can be found in Supplemental Table S5.
Serum CK, a biomarker of muscle disease activity, was tested at
baseline, two weeks treatment, and after two weeks wash-out (Fig. 4).
After two weeks washout (Week 4), mean (± SD) decreases in CK
Table 3
Change in bone turnover biomarkers pre and post 14 days of vamorolone
therapy. Abbreviations: CTXC- terminal telopeptide; P1NPprocollagen type 1
pro-peptide.
Vamorolone dose Biomarker Visit N Mean SD Paired t-test
p-value
0.25mg/kg/day Osteocalcin
(ng/mL)
Baseline 12 37.9 11.6 ns
Week 2 12 38.5 12
CTX (pg/mL) Baseline 11 871 161 ns
Week 2 12 964 158
P1NP (ng/mL) Baseline 12 556 185 0.01
Week 2 12 444 93.9
0.75mg/kg/day Osteocalcin
(ng/mL)
Baseline 8 34.8 7.7 ns
Week 2 10 34.8 9.1
CTX (pg/mL) Baseline 8 915 281 ns
Week 2 10 913 276
P1NP (ng/mL) Baseline 8 472 121 ns
Week 2 10 417 98.5
2.0mg/kg/day Osteocalcin
(ng/mL)
Baseline 10 40.8 6.13 ns
Week 2 10 36.5 9.16
CTX (pg/mL) Baseline 10 905 265 0.006
Week 2 10 675 172
P1NP (ng/mL) Baseline 10 519 96 <0.001
Week 2 10 341 72.9
6.0mg/kg/day Osteocalcin
(ng/mL)
Baseline 10 44.8 6.33 <0.001
Week 2 10 29.9 4.69
CTX (pg/mL) Baseline 10 904 203 <0.001
Week 2 10 649 205
P1NP (ng/mL) Baseline 10 516 116 <0.001
Week 2 10 310 59
Fig. 1. Pharmacokinetic (Cmax)/Pharmacodynamic (First-in-Morning Cortisol
Level) Analysis after 14 Days of Daily Vamorolone Therapy. Blood samples
were drawn in the morning pre-dose after 2 weeks of daily vamorolone therapy.
Each dot represents an individual patient. Adrenal suppression is defined as a
first-morning cortisol of< 3.6 μg/dL [100 nmol/L] (represented by the orange
line). Dot colors depict dose levels (purple= 6.0; green= 2.0; dark blue=
0.75; red= 0.25 mg/kg). (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article).
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from baseline were dose-dependent and ranged from 7074 ± 5624 U/
L (6.0 mg/kg) to 484 ± 14,365 U/L (0.25 mg/kg) U/L across the four
dose level groups. The decreases in mean CK values at Week 4 com-
pared to baseline were significant for the 2.0mg/kg (p=0.018) and
6.0 mg/kg (p= 0.003) daily dose level groups.
4. Discussion
We describe the first-in-patient clinical trial of vamorolone in boys
with DMD. The overall design of the trial was a multiple-ascending dose
study; safety and pharmacokinetics were measured as key outcomes.
Our findings demonstrated that vamorolone had an acceptable safety
and tolerability profile through the maximum daily dose tested
(6.0 mg/kg) in patients with DMD. The half-life of vamorolone is quite
short (2 h) and similar to glucocorticoids such as prednisolone, with no
evidence of drug accumulation between daily doses. The pharmacoki-
netics of vamorolone in 4 to< 7 year old boys with DMD were essen-
tially dose-proportional (linear) and similar to that in healthy adult
volunteers [9].
Pharmacodynamic safety biomarkers bridged to clinical outcomes
suggest improved safety of vamorolone compared to glucocorticoids in
DMD boys. Glucocorticoids cause increased fasting insulin and glucose
at doses of 0.2mg/kg/day or lower, following 1–2 weeks of treatment
[18]. Our data suggest that vamorolone does not share safety concerns
of insulin resistance with glucocorticoids following 2 weeks of treat-
ment, although at the 6.0 mg/kg dose, increasing insulin levels suggest
possible early development of insulin resistance. Long-term treatment
with vamorolone and measures of glycosylated hemoglobin will better
address clinical significance. In the Phase I VBP15-001 study of va-
morolone in healthy adult volunteers, there was no evidence of insulin
Fig. 2. Line graphs of exploratory safety biomarkers demonstrating absolute change in Relative Fluorescence Units (RFU) from Baseline to Day 14 in VBP15-002.
Shown are 4 dose levels. Baseline values were compared with Day 14 values using a two-tailed paired t-test. Asterisks (*) indicate significant increases from baseline
(pre-dose) to following 2 weeks of treatment (post-dose) for a given dose level (p<0.05). Abbreviations: BL=baseline; RFU=Relative Fluorescence Units;
MMP3=matrix metalloproteinase 3; IGFBP5= insulin-like growth factor binding protein-5.
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Fig. 3. Line graphs of exploratory efficacy
biomarkers demonstrating absolute change in
Relative Fluorescence Units (RFU) from
Baseline to Day 14 in VBP15-002. Shown are 4
dose levels. Baseline values were compared
with Day 14 values using a two-tailed paired t-
test. Asterisks (*) indicate significant increases
from baseline (pre-dose) to following 2 weeks
of treatment (post-dose) for a given dose level
(p < 0.05). Abbreviations: BL=baseline;
RFU=Relative Fluorescence Units;
MDC=macrophage-derived chemokine; IL22
BP= interleukin-22 binding protein;
IGFBP2= insulin-like growth factor binding
protein 2; ITGA1 ITGB1= integrin a1b1; MMP
12=matrix metalloproteinase 12.
Fig. 4. Change in CK activity from baseline to 2 weeks of daily
vamorolone treatment, and from baseline to 4 weeks (following 2
weeks of daily vamorolone dosing, and 2 weeks washout) in
VBP15-002. Shown is the mean percent change ± standard de-
viation. Baseline values were compared using a two-tailed paired
t-test; there was no adjustment for multiple comparisons. Asterisks
(*) indicate significant p-value<0.05). There was a significant
decrease in CK activity from baseline to 4 weeks after daily dosing
with 2.0 and 6.0 mg/kg of vamorolone. Abbreviations:
CK= creatine kinase.
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or glucose changes in a similar two-week multiple ascending dose de-
sign (1.0, 3.0, 9.0 and 20.0mg/kg/day dose groups) [9].
Treatment with glucocorticoids leads to both acute and chronic
suppression of the adrenal axis. Treatment with vamorolone led to some
adrenal suppression in both boys with DMD (this study) and in healthy
adult volunteers [9]. Dose-response data for adrenal suppression in
DMD patients treated with glucocorticoids is not available for com-
parison, but in adult volunteers we found about a 10-fold improvement
(dose/dose) compared to effects of prednisone [9,18].
Glucocorticoids cause decreases in osteocalcin (biomarker for bone
formation) and increases in CTX (biomarker for bone resorption), and
these changes can be correlated with bone morbidities. As shown in
Table 3, boys with DMD treated with daily vamorolone showed dose-
related decreases in both bone formation (osteocalcin; 6.0mg/kg) and
bone resorption (CTX; 2.0 and 6.0 mg/kg) biomarkers, the latter in
contrast to glucocorticoids [18]. Children undergo linear growth and
bone modeling, which correlates with an increase in bone turnover
markers. As with adrenal suppression, dose-response data regarding
bone biomarker changes in children with DMD treated with prednisone
are not available. However, studies have demonstrated decreased bone
turnover in boys with DMD treated with glucocorticoids [29,30]. An-
other study showed that in ambulatory boys with DMD, there are ele-
vations in bone resorption above ranges seen in healthy children, in-
dependent of treatment with glucocorticoids [31]. Serum osteocalcin is
reduced in both deflazacort and prednisone-treated DMD boys and in
other subjects without DMD [29,31–34]. Comparing published data of
DMD boys treated with glucocorticoids and DMD boys treated with
vamorolone, vamorolone significantly reduced osteocalcin at a daily
dose of 6.0mg/kg and above, whereas prednisone induced similar re-
ductions in osteocalcin at a daily dose of 0.75mg/kg (∼10-fold dif-
ference). The reduced potency of vamorolone in decreasing bone for-
mation markers relative to prednisone, coupled with the opposite effect
of the two drugs on bone resorption markers, and the lack of any
changes of these markers in adult volunteers through 20mg/kg of daily
dosing [9] suggests the potential for improvement in bone safety with
vamorolone compared to traditional glucocorticoids. This reduction in
an important safety concern was also demonstrated in preclinical stu-
dies [10].
Exploratory efficacy biomarkers showed compelling dose-re-
sponsive anti-inflammatory effects (Fig. 3). Serum CD23, also known as
a low affinity immunoglobulin epsilon Fc receptor (FCER2) is expressed
on B cells and antigen-presenting cells [35]. Cross-linking of CD23
mediates the activation of human macrophage inflammatory reaction
and pro-inflammatory cytokine production [36]. Vamorolone led to a
decrease in CD23 at the 2.0mg/kg and 6.0mg/kg daily dose in boys
with DMD, in a dose-responsive pattern, after 2 weeks of treatment
(Fig. 3). Macrophage-derived chemokine (MDC), also known as Che-
mokine (C-C) motif chemokine 22 (CCL22), plays a role in the traf-
ficking of activated T lymphocytes to inflammatory sites [37]. Two
weeks of daily vamorolone treatment led to significantly decreased
MDC at the 6.0 mg/kg dose in boys with DMD (Fig. 3). IL22 Binding
Protein (IL22BP), also known as IL22RA, is the soluble receptor of In-
terleukin 22 (IL-22). IL-22 is a pro-inflammatory cytokine produced by
cells in both innate and acquired immune responses. Elevated circu-
lating levels of IL22BP can be seen in inflammatory diseases such as
psoriasis, rheumatoid arthritis, and interstitial lung diseases [38]. Va-
morolone decreased IL-22BP in a dose-dependent manner, with statis-
tical significance at the 2.0 and 6.0mg/kg dose levels (Fig. 3). Taken
together, the exploratory biomarkers for efficacy provide compelling
evidence of the anti-inflammatory mechanism of action of vamorolone.
These anti-inflammatory effects would be expected to benefit muscle
pathology in DMD [2], as well as increase dystrophin levels in Becker
muscular dystrophy [39,40].
An additional exploratory biomarker of efficacy tested was serum
CK, a marker of muscle disease activity. Dose-dependent decreases in
CK were seen at 2 weeks following the last of 14 daily doses of
vamorolone in the two highest dose groups (Fig. 4). We hypothesize
that the membrane-stabilizing effects of vamorolone, or anti-in-
flammatory activity, or both could lead to reductions in disease activity
and observed reductions in serum CK that persist for two weeks after
completion of two weeks of daily drug dosing.
4.1. Conclusions
Biomarker data indicate that vamorolone has an improved safety
profile compared with prednisone. Biomarkers demonstrate proof-of-
concept that vamorolone has an anti-inflammatory mechanism of ac-
tion, and also offers the potential to stabilize the myofiber membrane.
In addition, bone turnover markers indicate an opposite, decreased
effect on bone resorption that could reflect the novel mineralocorticoid
receptor antagonism of vamorolone.
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